Integra LifeSciences Holdings Corporation (IART)
- Benzinga
Why Is Medical Device Maker Integra LifeSciences Stock Falling On Monday?
Monday, Integra LifeSciences Holdings Corporation (NASDAQ:IART) reported first-quarter revenues of $368.9 million, down 3.1% Y/Y on a reported basis and 2.5% on an organic basis, beating the consensus of $361.96 million and the management guidance of $360 million to $365 million. Revenue increased by 1.6% on an organic basis, excluding Boston. Integra Lifesciences reported an adjusted EPS of $0.55, which is in line with the consensus and lower than $0.74 a year ago. The management had forecasted
- Zacks
Integra (IART) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Integra (IART) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- GlobeNewswire
Integra LifeSciences Reports First Quarter 2024 Financial Results
PRINCETON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2024. First Quarter 2024 Highlights First quarter revenues of $368.9 million declined 3.1% on a reported basis and declined 2.5% on an organic basis compared to the prior year. Revenue increased 1.6% on an organic basis excluding BostonFirst quarter GAAP earnings per diluted
